Table 1 Summary of studies included in the comparisons between MMRM and LOCF_ANCOVA
Study | Treatment Duration | Drug | Number of Patients | Drug Dose & Design |
|---|---|---|---|---|
1 | 9 weeks | Placebo | 122 | - |
Duloxetine | 123 | 60 mg/d (QD) | ||
2 | 9 weeks | Placebo | 139 | - |
Duloxetine | 128 | 60 mg/d (QD) | ||
3 | 8 weeks | Placebo | 70 | - |
Duloxetine | 70 | 40–120 mg/d (20 mg-60 mg BID) | ||
Fluoxetine | 33 | 20 mg/d (QD) | ||
4 | 8 weeks | Placebo | 75 | - |
Duloxetine | 82 | 40–120 mg/d (20 mg-60 mg BID) | ||
Fluoxetine | 37 | 20 mg/d (QD) | ||
5 | 8 weeks | Placebo | 90 | - |
Duloxetine | 91 | 40 mg/d (20 mg BID) | ||
Duloxetine | 84 | 80 mg/d (40 mg BID) | ||
Paroxetine | 89 | 20 mg/d (QD) | ||
6 | 8 weeks | Placebo | 89 | - |
Duloxetine | 86 | 40 mg/d (20 mg BID) | ||
Duloxetine | 91 | 80 mg/d (40 mg BID) | ||
Paroxetine | 87 | 20 mg/d (QD) | ||
7 | 8 weeks | Placebo | 93 | - |
Duloxetine | 95 | 80 mg/d (40 mg BID) | ||
Duloxetine | 93 | 120 mg/d (60 mg BID) | ||
Paroxetine | 86 | 20 mg/d (QD) | ||
8 | 8 weeks | Placebo | 99 | - |
Duloxetine | 93 | 80 mg/d (40 mg BID) | ||
Duloxetine | 103 | 120 mg/d (60 mg BID) | ||
Paroxetine | 97 | 20 mg/d (QD) |